{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:46:37Z","timestamp":1791323197822,"version":"4.3.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00262-014-1551-x","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T06:14:44Z","timestamp":1398147284000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine"],"prefix":"10.1007","volume":"63","author":[{"given":"Yinin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter C.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Czarkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Grosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Chianese-Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.4049\/jimmunol.168.11.5954","volume":"168","author":"V Appay","year":"2002","unstructured":"Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A et al (2002) Characterization of CD4(+) CTLs ex vivo. J Immunol 168:5954\u20135958","journal-title":"J Immunol"},{"key":"1551_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1084\/jem.161.5.1122","volume":"161","author":"PD Greenberg","year":"1985","unstructured":"Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161:1122\u20131134","journal-title":"J Exp Med"},{"key":"1551_CR3","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698\u20132703","journal-title":"N Engl J Med"},{"key":"1551_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/00002371-200411000-00007","volume":"27","author":"HT Khong","year":"2004","unstructured":"Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE et al (2004) Immunization of HLA-A*0201 and\/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27:472\u2013477","journal-title":"J Immunother"},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00002371-200307000-00007","volume":"26","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P et al (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349\u2013356","journal-title":"J Immunother"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1158\/1078-0432.CCR-04-0241","volume":"10","author":"R Wong","year":"2004","unstructured":"Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C et al (2004) Immune responses to a class II helper peptide epitope in patients with stage III\/IV resected melanoma. Clin Cancer Res 10:5004\u20135013","journal-title":"Clin Cancer Res"},{"key":"1551_CR7","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","volume":"26","author":"CL Slingluff Jr","year":"2008","unstructured":"Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M et al (2008) Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973\u20134980","journal-title":"J Clin Oncol"},{"key":"1551_CR8","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH et al (2013) A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 19:4228\u20134238","journal-title":"Clin Cancer Res"},{"key":"1551_CR9","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/eji.1830191209","volume":"19","author":"P Panina-Bordignon","year":"1989","unstructured":"Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19:2237\u20132242","journal-title":"Eur J Immunol"},{"key":"1551_CR10","first-page":"3012","volume":"7","author":"CL Slingluff Jr","year":"2001","unstructured":"Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH et al (2001) Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7:3012\u20133024","journal-title":"Clin Cancer Res"},{"key":"1551_CR11","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4049\/jimmunol.147.5.1512","volume":"147","author":"RP Johnson","year":"1991","unstructured":"Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM et al (1991) HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 147:1512\u20131521","journal-title":"J Immunol"},{"key":"1551_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1073\/pnas.97.1.400","volume":"97","author":"HM Zarour","year":"2000","unstructured":"Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr et al (2000) Melan-A\/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400\u2013405","journal-title":"Proc Natl Acad Sci USA"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1084\/jem.183.5.1965","volume":"183","author":"SL Topalian","year":"1996","unstructured":"Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A et al (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965\u20131971","journal-title":"J Exp Med"},{"key":"1551_CR14","first-page":"296","volume":"58","author":"H Kobayashi","year":"1998","unstructured":"Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H et al (1998) CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58:296\u2013301","journal-title":"Cancer Res"},{"key":"1551_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.189.5.871","volume":"189","author":"S Manici","year":"1999","unstructured":"Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C et al (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871\u2013876","journal-title":"J Exp Med"},{"key":"1551_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1084\/jem.189.5.767","volume":"189","author":"P Chaux","year":"1999","unstructured":"Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R et al (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767\u2013778","journal-title":"J Exp Med"},{"key":"1551_CR17","first-page":"3238","volume":"57","author":"T Halder","year":"1997","unstructured":"Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L et al (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57:3238\u20133244","journal-title":"Cancer Res"},{"key":"1551_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s002620050501","volume":"47","author":"K Li","year":"1998","unstructured":"Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C et al (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32\u201338","journal-title":"Cancer Immunol Immunother"},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2002-03-0933","volume":"101","author":"G Consogno","year":"2003","unstructured":"Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM et al (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038\u20131044","journal-title":"Blood"},{"key":"1551_CR20","doi-asserted-by":"crossref","first-page":"976383","DOI":"10.1155\/2013\/976383","volume":"2013","author":"D Benteyn","year":"2013","unstructured":"Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B et al (2013) Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013:976383","journal-title":"Biomed Res Int"},{"key":"1551_CR21","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686\u20132693","journal-title":"Ann Oncol"},{"key":"1551_CR22","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","volume":"15","author":"CL Slingluff Jr","year":"2009","unstructured":"Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB et al (2009) Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036\u20137044","journal-title":"Clin Cancer Res"},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF et al (2013) Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19:465\u2013472","journal-title":"Nat Med"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-013-1435-5","volume":"62","author":"EP Salerno","year":"2013","unstructured":"Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C et al (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete freund\u2019s adjuvant, with or without peptide. Cancer Immunol Immunother 62:1149\u20131159","journal-title":"Cancer Immunol Immunother"},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","volume":"179","author":"MS Bijker","year":"2007","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8+ CTL priming by exact peptide epitopes in incomplete freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179:5033\u20135040","journal-title":"J Immunol"},{"key":"1551_CR26","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.4049\/jimmunol.163.5.2928","volume":"163","author":"P Chaux","year":"1999","unstructured":"Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C et al (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928\u20132936","journal-title":"J Immunol"},{"key":"1551_CR27","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.160.5.2099","volume":"160","author":"DJ Kittlesen","year":"1998","unstructured":"Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J et al (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 160:2099\u20132106","journal-title":"J Immunol"},{"key":"1551_CR28","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.4049\/jimmunol.161.12.6985","volume":"161","author":"Y Kawakami","year":"1998","unstructured":"Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X et al (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161:6985\u20136992","journal-title":"J Immunol"},{"key":"1551_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1084\/jem.176.5.1453","volume":"176","author":"C Traversari","year":"1992","unstructured":"Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453\u20131457","journal-title":"J Exp Med"},{"key":"1551_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1084\/jem.179.3.921","volume":"179","author":"B Gaugler","year":"1994","unstructured":"Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E et al (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921\u2013930","journal-title":"J Exp Med"},{"key":"1551_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1073\/pnas.91.6.2105","volume":"91","author":"E Celis","year":"1994","unstructured":"Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW et al (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105\u20132109","journal-title":"Proc Natl Acad Sci USA"},{"key":"1551_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1084\/jem.183.2.527","volume":"183","author":"JC Skipper","year":"1996","unstructured":"Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y et al (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527\u2013534","journal-title":"J Exp Med"},{"key":"1551_CR33","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","volume":"154","author":"Y Kawakami","year":"1995","unstructured":"Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S et al (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961\u20133968","journal-title":"J Immunol"},{"key":"1551_CR34","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1126\/science.7513441","volume":"264","author":"AL Cox","year":"1994","unstructured":"Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J et al (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716\u2013719","journal-title":"Science"},{"key":"1551_CR35","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.4049\/jimmunol.162.11.6849","volume":"162","author":"LQ Huang","year":"1999","unstructured":"Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T et al (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 162:6849\u20136854","journal-title":"J Immunol"},{"key":"1551_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.180.1.347","volume":"180","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR et al (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347\u2013352","journal-title":"J Exp Med"},{"key":"1551_CR37","first-page":"766s","volume":"7","author":"P Romero","year":"2001","unstructured":"Romero P, Dutoit V, Rubio-Godoy V, Lienard D, Speiser D, Guillaume P et al (2001) CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res 7:766s\u2013772s","journal-title":"Clin Cancer Res"},{"key":"1551_CR38","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.4049\/jimmunol.157.11.5027","volume":"157","author":"JC Skipper","year":"1996","unstructured":"Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN et al (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from pmel-17\/gp100. J Immunol 157:5027\u20135033","journal-title":"J Immunol"},{"key":"1551_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00262-004-0592-y","volume":"54","author":"KT Hogan","year":"2005","unstructured":"Hogan KT, Sutton JN, Chu KU, Busby JA, Shabanowitz J, Hunt DF et al (2005) Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother 54:359\u2013371","journal-title":"Cancer Immunol Immunother"},{"key":"1551_CR40","first-page":"3598","volume":"161","author":"RF Wang","year":"1998","unstructured":"Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3598\u20133606","journal-title":"J Immunol"}],"updated-by":[{"DOI":"10.1007\/s00262-014-1601-4","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:00:00Z","timestamp":1409011200000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-014-1551-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1551-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T09:10:06Z","timestamp":1689153006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-014-1551-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,23]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s00262-014-1551-x","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s00262-014-1601-4","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,23]]},"assertion":[{"value":"10 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}